Results 11 to 20 of about 4,513 (159)
Scratching the surface: NK-1 inhibitors for chronic itch-Promise or placebo? [PDF]
J Eur Acad Dermatol VenereolJournal of the European Academy of Dermatology and Venereology, Volume 39, Issue 10, Page 1703-1704, October 2025.
Yosipovitch G.
europepmc +2 more sources
Aprepitant Inhibits JNK and p38/MAPK to Attenuate Inflammation and Suppresses Inflammatory Pain
Frontiers in Pharmacology, 2022 Substance P contributes to the pathogenesis of pain by acting on NK-1R, specialized sensory neurons that detect noxious stimuli. Aprepitant, an antagonist of NK-1R, is widely used to treat chemotherapy-induced nausea and vomiting.
Yang Yang +7 more
doaj +1 more source
Frontiers in Public Health, 2021 Objectives: The aim of this systematic review is to assess the published cost-effectiveness analyses of aprepitant for patients with chemotherapy-induced nausea and vomiting (CINV).Methods: A systematic literature search was performed on PubMed, EMbase ...
Tingting Qiu +6 more
doaj +1 more source
Influence of aprepitant on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits [PDF]
PeerJ, 2018 Background Concomitant drug administration is a general phenomenon in patients with chronic diseases such as diabetes mellitus. Among the currently available oral antidiabetic drugs, gliclazide is a commonly prescribed drug considering its multiple ...
Raghunandan Reddy Kura +2 more
doaj +2 more sources
CAQ Corner: Basic concepts of transplant immunology
, 2022 Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley +1 more source
Anti‐Metastatic Effects of Aprepitant on Glioblastoma Cells: Targeting the Substance P/Neurokinin‐1 Pathway [PDF]
Cancer MedABSTRACT Background Glioblastoma (GB) is an aggressive brain tumor characterized by rapid proliferation, invasion, and resistance to therapy. The substance P (SP)/neurokinin‐1 receptor (NK‐1R) pathway contributes to GB progression by promoting angiogenesis, inflammation, and extracellular matrix remodeling. Aprepitant, an FDA‐approved NK‐1R antagonist,
Engür‐Öztürk S +2 more
europepmc +2 more sources
Indian Journal of Anaesthesia, 2021 Background and Aims: This study was designed to compare the effectiveness of the combination of dexamethasone–ondansetron with oral aprepitant alone and triple combination therapy with all three agents (dexamethasone-ondansetron and oral aprepitant) in ...
Ingilala L Thanuja +3 more
doaj +1 more source
Biochemistry Research International, 2021 Introduction. Glioblastoma is the most malignant brain tumor with different therapeutic protocols, including surgery, radiotherapy, and chemotherapy. Substance P (SP), a peptide released by sensory nerves, increases cellular excitability by activating ...
Faranak Korfi +3 more
doaj +1 more source
Characterization and Pharmacokinetic Study of Aprepitant Solid Dispersions with Soluplus®
Molecules, 2015 Solid dispersions are a useful approach to improve the dissolution rate and bioavailability of poorly water-soluble active pharmaceutical ingredients (APIs).
Jinwen Liu +7 more
doaj +1 more source
Virulence, 2020 With the rapid increase in the frequency of azole-resistant species, combination therapy appears to be a promising tool to augment the antifungal activity of azole drugs against resistant Candida species.
Hassan E. Eldesouky +3 more
doaj +1 more source